1952 CE
Incorporation as Pfizer (East Pakistan) Ltd
The company is incorporated as Pfizer (East Pakistan) Ltd, a wholly owned subsidiary of Pfizer Inc, to manufacture and distribute pharmaceuticals in East Pakistan. #pharma #history
Chronological Storyline (38 Milestones)
1971 CE
Transition during Bangladesh Liberation War
During the Bangladesh Liberation War, operations are disrupted. After independence, the company is reorganized as Pfizer Laboratories (Bangladesh) Ltd. #pharma #bangladesh
1972 CE
Renamed to Pfizer Laboratories (Bangladesh) Ltd
The company is officially renamed Pfizer Laboratories (Bangladesh) Ltd, continuing as a subsidiary of Pfizer. #pharma #corporate
1993 CE
Renaming to Renata Limited
The company is renamed Renata Limited following a strategic divestment from Pfizer and a joint venture with local investors, marking its independence. #pharma #milestone
1994 CE
Listing on Dhaka Stock Exchange
Renata Limited goes public with an IPO on the Dhaka Stock Exchange (DSE), raising capital for expansion. #finance #ipo
1995 CE
Launch of First Manufacturing Plant
The company establishes its first dedicated manufacturing facility in Dhaka, increasing production capacity for oral solids and liquids. #pharma #manufacturing
1998 CE
Introduction of Animal Health Products
Renata diversifies into animal health, launching veterinary pharmaceuticals and feed additives. #animalhealth #diversification
2000 CE
Expansion into Contract Manufacturing
Renata begins offering contract manufacturing services to multinational companies, leveraging its WHO-GMP certified facilities. #pharma #contractmanufacturing
2002 CE
Acquisition of Labaid Pharmaceuticals
Renata acquires Labaid Pharmaceuticals, strengthening its presence in the cardiology and diabetes segments. #acquisition #pharma
2003 CE
Launch of Nebulizer Line
Renata expands into respiratory devices, introducing a line of nebulizers and inhalers. #medicaldevices #respiratory
2005 CE
Establishment of R&D Center
A dedicated research and development center is opened in Dhaka to focus on generic drug formulation and biopharmaceuticals. #research #innovation
2006 CE
First Export to Myanmar
Renata begins exporting products to Myanmar, marking its first international market entry. #export #international
2007 CE
Launch of Oncology Division
Renata enters oncology with a range of generic cancer drugs, including cytotoxics and targeted therapies. #oncology #pharma
2008 CE
Receives WHO-GMP Certification
Renata's manufacturing facilities achieve WHO-GMP certification, enabling exports to regulated markets. #quality #certification
2009 CE
Acquisition of Medicon Pharmaceuticals
Renata acquires Medicon Pharmaceuticals to strengthen its generic portfolio and distribution network. #acquisition #pharma
2010 CE
Revenue Surpasses BDT 5 Billion
Renata's annual revenue crosses BDT 5 billion for the first time, driven by strong domestic sales and exports. #finance #growth
2011 CE
Launch of Biotech Division
Renata establishes a biotechnology division focusing on biosimilars and insulin, investing in state-of-the-art facilities. #biotech #biosimilars
2012 CE
Expansion to Nepal and Sri Lanka
Renata enters the pharmaceutical markets of Nepal and Sri Lanka through distribution agreements. #expansion #southasia
2013 CE
Appointment of New CEO
M. A. Rahim appointed as Chief Executive Officer, leading a strategic shift towards high-value generics and biologics. #leadership #ceo
2014 CE
Launch of Insulin Glargine
Renata launches its first biosimilar insulin (insulin glargine) in Bangladesh, becoming a pioneer in the local biopharma sector. #diabetes #biosimilar
2015 CE
Acquisition of Nuvista Pharma
Renata acquires Nuvista Pharma to expand its presence in the antibiotic and central nervous system segments. #acquisition #pharma
2016 CE
Entry into African Markets
Renata begins exporting to Kenya and Nigeria, leveraging WHO-GMP certification for access to African markets. #export #africa
2017 CE
Revenue Reaches BDT 10 Billion
Annual revenue exceeds BDT 10 billion, reflecting consistent growth and market share expansion. #finance #milestone
2018 CE
Launch of Biosimilar Rituximab
Renata launches rituximab biosimilar for oncology and autoimmune diseases, expanding its biologics portfolio. #biosimilar #oncology
2019 CE
Partnership with AstraZeneca
Renata signs a strategic partnership with AstraZeneca for the distribution of selected products in Bangladesh. #partnership #pharma
2020 CE
COVID-19 Response and Remdesivir Launch
During the pandemic, Renata rapidly launches generic remdesivir and other COVID-19 therapeutics, scaling up production. #covid19 #pharma
2020 CE
Market Capitalization Tops BDT 100 Billion
Renata's market cap on the DSE surpasses BDT 100 billion, reflecting investor confidence and strong performance. #finance #stockmarket
2021 CE
Launch of First mRNA Vaccine Manufacturing Capability
Renata invests in mRNA vaccine technology and partners with global entities to produce COVID-19 vaccines locally. #vaccine #biotech
2021 CE
Acquisition of Custom Pharma (UK)
Renata acquires Custom Pharma Ltd, a UK-based contract development and manufacturing organization (CDMO), marking its first overseas acquisition. #acquisition #cdmo
2022 CE
Expansion of Animal Health Business
Renata launches a new animal health production facility in Gazipur, doubling its veterinary product capacity. #animalhealth #expansion
2022 CE
Revenue Exceeds BDT 20 Billion
Annual revenue crosses BDT 20 billion, driven by strong exports and domestic growth. #finance #growth
2023 CE
Inauguration of Oncology Plant
A dedicated oncology manufacturing facility is inaugurated in Savar, enhancing capacity for cytotoxic drugs. #oncology #manufacturing
2023 CE
Launch of Gene Therapy Research Program
Renata announces a gene therapy research program in collaboration with international academic institutions. #genetherapy #research
2024 CE
Partnership with Moderna for COVID-19 Vaccine
Renata signs an agreement with Moderna to manufacture and distribute its mRNA COVID-19 vaccine in Bangladesh. #vaccine #partnership
2024 CE
DSE Top 10 by Market Cap
Renata remains among the top 10 companies on the Dhaka Stock Exchange by market capitalization, reflecting sustained investor trust. #finance #dse
2025 CE
Launch of Biosimilar Trastuzumab
Renata launches trastuzumab biosimilar for breast cancer, expanding its oncology biosimilars portfolio. #biosimilar #breastcancer
2025 CE
Completion of Third Biotech Plant
Renata completes construction of a third biotech manufacturing facility, increasing biosimilar capacity by 50%. #biotech #expansion
2025 CE
Revenue Guidance of BDT 30 Billion
Renata projects annual revenue of BDT 30 billion, driven by exports to new markets in Southeast Asia and Africa. #finance #guidance